Singapore markets closed
Straits Times Index
3,292.93 -3.96 (-0.12%) Nikkei
38,236.07 -37.98 (-0.10%) Hang Seng
18,475.92 +268.79 (+1.48%) FTSE 100
8,209.34 +37.19 (+0.46%) Bitcoin USD
61,583.45 +2,314.94 (+3.91%) CMC Crypto 200
1,324.03 +47.05 (+3.69%)
BioInvent International AB (publ) (BINV.ST)
Stockholm - Stockholm Real-time price. Currency in SEK
Add to watchlist
At close: 05:29PM CEST
| Previous close | 26.35 |
| Open | 26.40 |
| Bid | 26.55 x 0 |
| Ask | 26.60 x 0 |
| Day's range | 26.15 - 27.10 |
| 52-week range | 14.00 - 29.40 |
| Volume | |
| Avg. volume | 70,586 |
| Market cap | 1.773B |
| Beta (5Y monthly) | 0.33 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -5.08 |
| Earnings date | 24 Apr 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 56.50 |
PR NewswireCASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma In China
CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products, and BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced preliminary encouraging efficacy data for BI-1206 in combination with rituximab in patients
© 2024 Yahoo. All rights reserved.